Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
$36.16
-0.8%
$47.72
$33.40
▼
$109.00
$1.23B1.441.06 million shs263,265 shs
Urogen Pharma stock logo
URGN
Urogen Pharma
$28.69
+2.1%
$36.68
$16.50
▼
$50.81
$1.41B1.68881,331 shs1.48 million shs
Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
-2.23%-3.67%+1.84%-50.52%-35.71%
Urogen Pharma stock logo
URGN
Urogen Pharma
+7.33%+6.80%-18.69%-42.56%+18.27%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
$36.16
-0.8%
$47.72
$33.40
▼
$109.00
$1.23B1.441.06 million shs263,265 shs
Urogen Pharma stock logo
URGN
Urogen Pharma
$28.69
+2.1%
$36.68
$16.50
▼
$50.81
$1.41B1.68881,331 shs1.48 million shs
Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
-2.23%-3.67%+1.84%-50.52%-35.71%
Urogen Pharma stock logo
URGN
Urogen Pharma
+7.33%+6.80%-18.69%-42.56%+18.27%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
2.69
Moderate Buy$130.33260.42% Upside
Urogen Pharma stock logo
URGN
Urogen Pharma
2.70
Moderate Buy$53.3886.04% Upside

Current Analyst Ratings Breakdown

Latest URGN and NKTR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/16/2026
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
Lower Price TargetBuy$153.00 ➝ $149.00
11/5/2026
Urogen Pharma stock logo
URGN
Urogen Pharma
Set Price Target$60.00
11/5/2026
Urogen Pharma stock logo
URGN
Urogen Pharma
Reiterated RatingOutperform
11/5/2026
Urogen Pharma stock logo
URGN
Urogen Pharma
Lower Price TargetBuy$58.00 ➝ $56.00
10/28/2026
Urogen Pharma stock logo
URGN
Urogen Pharma
Reiterated RatingOutperform
10/19/2026
Urogen Pharma stock logo
URGN
Urogen Pharma
Reiterated RatingBuy$75.00
10/15/2026
Urogen Pharma stock logo
URGN
Urogen Pharma
Reiterated RatingSell (D-)
10/12/2026
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
Initiated CoverageOverweight ➝ Neutral$53.00
10/12/2026
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
UpgradeHold
10/12/2026
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
Initiated CoverageOutperform$130.00
10/9/2026
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
Reiterated RatingBuy$178.00
(Data available from 11/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
$55.23M22.35N/AN/A$4.41 per share8.20
Urogen Pharma stock logo
URGN
Urogen Pharma
$250.25M5.62N/AN/A($2.55) per share-11.25
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
-$164.08M-$6.46N/AN/AN/A-339.67%-33.89%-24.86%N/A
Urogen Pharma stock logo
URGN
Urogen Pharma
-$153.49M-$1.32N/A10.91N/A-26.27%N/A-26.88%N/A

Latest URGN and NKTR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/12/2026Q3 2026
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
-$2.07-$1.63+$0.44-$1.63$10.27 million$9.39 million
11/4/2026Q3 2026
Urogen Pharma stock logo
URGN
Urogen Pharma
$0.1057-$0.03-$0.1357-$0.03$89.92 million$89.00 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
N/AN/AN/AN/AN/A
Urogen Pharma stock logo
URGN
Urogen Pharma
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
N/A
10.42
10.42
Urogen Pharma stock logo
URGN
Urogen Pharma
N/A
3.40
3.06

Institutional Ownership

CompanyInstitutional Ownership
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
75.88%
Urogen Pharma stock logo
URGN
Urogen Pharma
91.29%

Insider Ownership

CompanyInsider Ownership
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
2.50%
Urogen Pharma stock logo
URGN
Urogen Pharma
4.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
6334.14 million33.29 millionOptionable
Urogen Pharma stock logo
URGN
Urogen Pharma
29149.05 million46.69 millionOptionable

Recent News About These Companies

UroGen Earnings Call Highlights Zosturi Growth, 2027 Pipeline
Urogen Pharma (NASDAQ:URGN) Shares Gap Down - What's Next?
UroGen: Opportunity Builds As Rough Patch Gets Brutal
FY2026 EPS Estimate for Urogen Pharma Lifted by Analyst
Urogen Pharma (NASDAQ:URGN) Shares Down 16.3% Following Weak Earnings
UroGen Pharma Ltd. (URGN) Q3 2026 Earnings Call Transcript
UroGen (URGN) Q3 2026 Earnings Call Transcript
Urogen Pharma Q3 Earnings Call Highlights
The Gel That Became a Business
UroGen Pharma Shares Fall After Q3 Results Miss Estimates

New MarketBeat Followers Over Time

Media Sentiment Over Time

Nektar Therapeutics stock logo

Nektar Therapeutics NASDAQ:NKTR

$36.16 -0.28 (-0.76%)
As of 02:12 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.

Urogen Pharma stock logo

Urogen Pharma NASDAQ:URGN

$28.69 +0.59 (+2.10%)
As of 02:12 PM Eastern
This is a fair market value price provided by Massive. Learn more.

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.